> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CGMP Issues at Private Label Grooming
- URL: https://www.fdaweb.com/cgmp-issues-at-private-label-grooming/
- Published: 2025-08-12T12:00:00.000Z
- Updated: 2026-09-14T15:18:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159662

A 2/18-2/20 FDA inspection at Gussyup, doing business as Private Label Grooming in Henderson, NV, identified significant violations of current good manufacturing practice (CGMP) regulations for finished drugs. A just-released 7/9 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gussyup-llc-dba-private-label-grooming-709488-07092025?ref=fdaweb.com) says the specific violations were:

- failure of the firm’s quality control unit to exercise its responsibility to ensure that manufactured drug products comply with CGMP, and meet established specifications for identity, strength, quality, and purity; and
- failure to conduct at least one test to verify the identity of each component of a drug product, and failure to validate and establish the reliability of a component supplier’s test analyses at appropriate intervals.

FDA acknowledges the firm’s stated commitment to cease production of all over-the-counter drugs at this facility and the discontinuation of its FDA drug registration. The agency asks Gussyup to clarify whether it intends to resume drug production at the facility in the future.

FDA recommends that Gussyup retain a qualified consultant to evaluate its operations and assist it in meeting CGMP requirements.

The firm was told to correct the violations promptly and to respond with a list of specific actions it has taken to address the violations and prevent their recurrence, with a schedule for completing the corrections.